FDA Details Expectations For Approval Of New Painkillers
Law360, New York (February 6, 2014, 8:33 PM EST) -- The U.S. Food and Drug Administration on Wednesday described its current expectations for development and testing of painkillers, outlining key standards for a drug class whose sometimes addictive properties have led to tremendous controversy and litigation.
In its draft guidance, the FDA discussed how its clinical trial demands will vary greatly depending on the type of painkiller or analgesic that is being studied. For example, a reformulated version of a previously approved medicine may need only one additional trial to prove safety and effectiveness, regulators said.
On the other end of the spectrum, manufacturers who want to sell an entirely new...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!